IR

Corestem is a biopharmaceutical company that researches and commercializes stem cell technology.

Finances

(Unit: 1.0M KRW)
Condensed financial statement
Category 2021.12.31 2020.12.31 2019.12.31
Current assets 76,522 101,760 44,816
Quick assets 76,068 101,760 44,400
Inventories 454 365 416
Non-Current assets 59,887 41,111 40,832
Investments 151 162 173
Tangible assets 44,927 32,039 29,890
Intangible assets 5,575 4,689 4,692
Other non-current assets 9,234 4,221 2,071
Deferred tax assets - - 3,736
Total assets 136,408 142,871 85,648
[Current Liabilities] 62,162 68,691 6,945
[Non-current liabilities] 8,827 6,623 4,150
Total liabilities 70,989 75,314 11,095
[Equity attributable to owners of parent] 37,191 41,286 57,696
Issued capital 7,935 7,859 7,859
Capital surplus 58,265 54,967 54,967
Other stockholder’s equity 16,444 16,271 8,989
Retained earning (45,454) (37,811) (14,119)
Non-controlling interest 28,228 26,271 16,856
Total equity 65,419 67,557 74,553
Category The 19th (2021.01.01~2021.12.31) The 18th (2020.01.01~2020.12.31) The 17th (2019.01.01~2019.12.31)
Revenue (Sales) 30,240 26,358 24,284
Operating lose (10,550) (4,998) (5,088)
Consolidated Net Income (4,996) (22,384) (4,370)
Controlling interest (6,999) (23,187) (5,168)
Net-Controlling Interests Equity 2,003 803 798
Total Comprehensive Income (5,685) (22,776) (3,544)
Ownership of parent company (5,640) (23,692) (4,841)
Non-controlling interest net income 2003 916 1,298
Earnings per share - - -
Basic earnings (loss) per share (Unit : KRW) (444) (1,475) (329)
Diluted earnings (loss) per share (Unit : KRW) (643) (1,475) (329)
Number of Companies included in the consolidation 2개사 2개사 2개사
(Unit: 1.0M KRW)